AR065878A1 - Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer - Google Patents
Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancerInfo
- Publication number
- AR065878A1 AR065878A1 ARP080101305A ARP080101305A AR065878A1 AR 065878 A1 AR065878 A1 AR 065878A1 AR P080101305 A ARP080101305 A AR P080101305A AR P080101305 A ARP080101305 A AR P080101305A AR 065878 A1 AR065878 A1 AR 065878A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- cell
- agent
- group
- fibroblast
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 11
- 201000011510 cancer Diseases 0.000 title abstract 11
- 210000004027 cell Anatomy 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 210000002950 fibroblast Anatomy 0.000 abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 210000002744 extracellular matrix Anatomy 0.000 abstract 3
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
- 102000053642 Catalytic RNA Human genes 0.000 abstract 1
- 108090000994 Catalytic RNA Proteins 0.000 abstract 1
- 102000005600 Cathepsins Human genes 0.000 abstract 1
- 108010084457 Cathepsins Proteins 0.000 abstract 1
- 101150021185 FGF gene Proteins 0.000 abstract 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 1
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 abstract 1
- -1 PDGF Proteins 0.000 abstract 1
- 102100027287 Serpin H1 Human genes 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 abstract 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229960003471 retinol Drugs 0.000 abstract 1
- 235000020944 retinol Nutrition 0.000 abstract 1
- 239000011607 retinol Substances 0.000 abstract 1
- 108091092562 ribozyme Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Droga para el tratamiento del cáncer y un método para el tratamiento del mismo. Este objeto puede ser alcanzado mediante un agente, que contiene un retinoide, con blanco en o direccionado a una célula seleccionada a partir del grupo que consiste deuna célula cancerosa y un fibroblasto asociado a cáncer, un portador de entrega de sustancia hacia la célula, el portador conteniendo el agente direccionado, una composicion anti-cáncer, una composicion anti-fibroblasto asociado a cáncer, y unmétodo de tratamiento de cáncer que utiliza el agente direccionado o el portador. Reivindicacion 1: Un agente direccionado a una célula seleccionada a partir del grupo que consiste de una célula cancerosa y un fibroblasto asociado a cáncer,comprendiendo el agente direccionado un retinoide. Reivindicacion 2: El agente direccionado de acuerdo con la reivindicacion 1, en donde el retinoide comprende retinol. Reivindicacion 9: La composicion de acuerdo con cualquiera de lasreivindicaciones 6 a 8, en donde la droga que controla la actividad o crecimiento de un fibroblasto asociado a cáncer está seleccionada a partir del grupo que consiste de un inhibidor de la actividad o produccion de una sustancia bioactivaseleccionada a partir del grupo que consiste de TGF-beta, HGF, PDGF, VEGF, IGF, MMP, FGF, uPA, catepsina, y SDF-1, un supresor de la actividad celular, un inhibidor de crecimiento, un inductor de apoptosis, y un siRNA, ribozima, ácido nucleicoantisentido, polinucleotido quimérico de DNA/RNA, o vector que expresa el mismo, que se direcciona a una o más moléculas de entre una molécula constituyente de la matriz extracelular producida por fibroblastos asociados a cáncer y una moléculainvolucrada en la produccion o secrecion de la molécula constituyente de la matriz extracelular. Reivindicacion 10: La composicion de acuerdo con la reivindicacion 9, en donde la molécula involucrada en la produccion o secrecion de la moléculaconstituyente de la matriz extracelular es HSP47.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007091808 | 2007-03-30 | ||
JP2007261202 | 2007-10-04 | ||
JP2007324459 | 2007-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065878A1 true AR065878A1 (es) | 2009-07-08 |
Family
ID=39808395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101305A AR065878A1 (es) | 2007-03-30 | 2008-03-28 | Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer |
Country Status (11)
Country | Link |
---|---|
US (2) | US8686052B2 (es) |
EP (1) | EP2135600B1 (es) |
JP (4) | JP5302187B2 (es) |
KR (1) | KR101585947B1 (es) |
CN (1) | CN101674810B (es) |
AR (1) | AR065878A1 (es) |
AU (1) | AU2008233550B2 (es) |
CA (1) | CA2682493A1 (es) |
ES (1) | ES2793673T3 (es) |
TW (1) | TWI407971B (es) |
WO (1) | WO2008120815A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7685050B2 (en) * | 2001-12-13 | 2010-03-23 | Bgc Partners, Inc. | Systems and methods for improving the liquidity and distribution network for luxury and other illiquid items |
US7358223B2 (en) * | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
ES2443229T3 (es) | 2004-12-22 | 2014-02-18 | Nitto Denko Corporation | Portador de fármacos y kit portador de fármacos para la inhibición de la fibrosis |
JP2009221164A (ja) * | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
TWI407971B (zh) * | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
CN101970012A (zh) * | 2007-09-14 | 2011-02-09 | 日东电工株式会社 | 药物载体 |
TW201630627A (zh) * | 2008-09-12 | 2016-09-01 | 日東電工股份有限公司 | 纖維化疾病之造影劑 |
ES2712086T3 (es) * | 2010-06-17 | 2019-05-09 | Nitto Denko Corp | Agente para tratar la fibrosis renal |
JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
JP2014500258A (ja) * | 2010-11-15 | 2014-01-09 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 制御放出粘膜付着システム |
WO2012176282A1 (ja) | 2011-06-21 | 2012-12-27 | 日東電工株式会社 | アポトーシス誘導剤 |
CN103917248A (zh) * | 2011-11-18 | 2014-07-09 | 日东电工株式会社 | 肠纤维化处理剂 |
JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
JP6076076B2 (ja) | 2012-12-21 | 2017-02-08 | 日東電工株式会社 | 組織再生促進剤 |
US10004723B2 (en) * | 2013-04-19 | 2018-06-26 | University Of Saskatchewan | Aromatase inhibitor-releasing intravaginal device |
US10556117B2 (en) | 2013-05-06 | 2020-02-11 | Medtronic, Inc. | Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead |
US10471267B2 (en) | 2013-05-06 | 2019-11-12 | Medtronic, Inc. | Implantable cardioverter-defibrillator (ICD) system including substernal lead |
US10668270B2 (en) | 2013-05-06 | 2020-06-02 | Medtronic, Inc. | Substernal leadless electrical stimulation system |
CN104374918B (zh) * | 2013-08-17 | 2016-11-09 | 复旦大学 | 热休克蛋白47胶质瘤相关肿瘤抗原及应用 |
CN106164089B (zh) * | 2014-04-02 | 2020-11-03 | 日东电工株式会社 | 靶向分子及其用途 |
CA2943733C (en) | 2014-04-07 | 2022-03-01 | Nitto Denko Corporation | Polymer-based hydrotropes for hydrophobic drug delivery |
WO2015194522A1 (ja) | 2014-06-17 | 2015-12-23 | 日東電工株式会社 | アポトーシス誘導剤 |
US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
CN104825394B (zh) * | 2015-04-17 | 2018-08-17 | 北京大学 | 靶向肿瘤相关成纤维细胞的脂质体载药系统 |
US10792374B2 (en) | 2015-10-09 | 2020-10-06 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
KR20180086260A (ko) | 2015-12-13 | 2018-07-30 | 닛토덴코 가부시키가이샤 | 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조 |
EP3595636A4 (en) | 2017-03-16 | 2021-01-13 | Children's Medical Center Corporation | GENETICALLY PRODUCED LIPOSOMES AS TARGETED THERAPEUTICS AGAINST CANCER |
US20210260095A1 (en) * | 2018-08-22 | 2021-08-26 | Nitto Denko Corporation | Medicine using hsp47 inhibitor to enhance sensitivity to chemotherapeutic agent |
KR102173702B1 (ko) | 2018-11-27 | 2020-11-03 | 가톨릭대학교 산학협력단 | 피부 세포 표적용 펩타이드 및 이의 용도 |
RU2733230C1 (ru) * | 2019-12-16 | 2020-09-30 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 198 BlCan RLA |
RU2742244C1 (ru) * | 2020-05-20 | 2021-02-04 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 587 BlCan TVV |
RU2742245C1 (ru) * | 2020-05-20 | 2021-02-04 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 398 BlCan KAE |
CN115997122A (zh) * | 2020-06-26 | 2023-04-21 | 拉夸里亚创药株式会社 | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 |
KR20230072259A (ko) | 2021-11-17 | 2023-05-24 | 사회복지법인 삼성생명공익재단 | Prrx1 억제제를 포함하는 암 예방 또는 치료용 약학 조성물 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4665913A (en) * | 1983-11-17 | 1987-05-19 | Lri L.P. | Method for ophthalmological surgery |
US4669466A (en) * | 1985-01-16 | 1987-06-02 | Lri L.P. | Method and apparatus for analysis and correction of abnormal refractive errors of the eye |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US5811119A (en) | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
US5258791A (en) * | 1990-07-24 | 1993-11-02 | General Electric Company | Spatially resolved objective autorefractometer |
US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5144630A (en) * | 1991-07-29 | 1992-09-01 | Jtt International, Inc. | Multiwavelength solid state laser using frequency conversion techniques |
CA2073802C (en) * | 1991-08-16 | 2003-04-01 | John Shimmick | Method and apparatus for combined cylindrical and spherical eye corrections |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
DE4232915A1 (de) * | 1992-10-01 | 1994-04-07 | Hohla Kristian | Vorrichtung zur Formung der Cornea durch Abtragen von Gewebe |
US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
US5520679A (en) * | 1992-12-03 | 1996-05-28 | Lasersight, Inc. | Ophthalmic surgery method using non-contact scanning laser |
US5820879A (en) | 1993-02-12 | 1998-10-13 | Access Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition |
US5753261A (en) | 1993-02-12 | 1998-05-19 | Access Pharmaceuticals, Inc. | Lipid-coated condensed-phase microparticle composition |
US5785976A (en) | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
US5460627A (en) * | 1993-05-03 | 1995-10-24 | O'donnell, Jr.; Francis E. | Method of evaluating a laser used in ophthalmological surgery |
CO4230054A1 (es) * | 1993-05-07 | 1995-10-19 | Visx Inc | Metodo y sistemas para tratamiento con laser de errores refractivos utilizando formacion de imagenes de desplazamiento |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5942230A (en) | 1994-05-06 | 1999-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Composition of immunotoxins and retinoids and use thereof |
JPH08180824A (ja) * | 1994-12-22 | 1996-07-12 | Hitachi Ltd | 電子線源、その製造方法、電子線源装置及びそれを用いた電子線装置 |
US5646791A (en) * | 1995-01-04 | 1997-07-08 | Visx Incorporated | Method and apparatus for temporal and spatial beam integration |
US5534261A (en) | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
US6187315B1 (en) | 1995-03-03 | 2001-02-13 | Atajje, Inc. | Compositions and methods of treating cancer with tannin complexes |
US5666117A (en) * | 1995-08-31 | 1997-09-09 | The United State Of American As Represented By The Secretary Of The Navy | Non-Return to Zero Level to Bi-Phase signal converter |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
US5782822A (en) * | 1995-10-27 | 1998-07-21 | Ir Vision, Inc. | Method and apparatus for removing corneal tissue with infrared laser radiation |
CN101028259A (zh) | 1996-03-12 | 2007-09-05 | Pg-Txl有限公司 | 水溶性紫杉醇产品 |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6238917B1 (en) | 1996-04-02 | 2001-05-29 | Commonwealth Scientific Industrial Research Organizaion | Asymmetric hammerhead ribozymes |
US5742626A (en) * | 1996-08-14 | 1998-04-21 | Aculight Corporation | Ultraviolet solid state laser, method of using same and laser surgery apparatus |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US6271914B1 (en) * | 1996-11-25 | 2001-08-07 | Autonomous Technologies Corporation | Objective measurement and correction of optical systems using wavefront analysis |
US20010041884A1 (en) * | 1996-11-25 | 2001-11-15 | Frey Rudolph W. | Method for determining and correcting vision |
US5777719A (en) * | 1996-12-23 | 1998-07-07 | University Of Rochester | Method and apparatus for improving vision and the resolution of retinal images |
US6090102A (en) * | 1997-05-12 | 2000-07-18 | Irvision, Inc. | Short pulse mid-infrared laser source for surgery |
FR2763853B1 (fr) | 1997-05-28 | 2000-01-07 | Oreal | Association d'un retinoide avec un polymere polyamine |
US6656734B1 (en) | 1997-07-01 | 2003-12-02 | Transgene S.A. | Compositions for the delivery of polynucleotides to cells |
US6037481A (en) | 1997-08-08 | 2000-03-14 | Industria E Comercio De Cosmeticos Natura Ltda | Process for stabilizing levogyre ascorbic acid (LAA), a stable aqueous LAA composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment |
US6072101A (en) | 1997-11-19 | 2000-06-06 | Amcol International Corporation | Multicomponent superabsorbent gel particles |
AU4193199A (en) | 1998-05-20 | 1999-12-06 | Expression Genetics, Inc. | A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier |
US6000800A (en) * | 1998-06-22 | 1999-12-14 | Schepens Eye Research Institute | Coaxial spatially resolved refractometer |
US6099125A (en) * | 1998-12-07 | 2000-08-08 | Schepens Eye Research Foundation | Coaxial spatially resolved refractometer |
US6004313A (en) * | 1998-06-26 | 1999-12-21 | Visx, Inc. | Patient fixation system and method for laser eye surgery |
GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
US6347549B1 (en) * | 1998-07-09 | 2002-02-19 | Ryan International Corporation | Enhancement of storm location from a single moving platform |
MXPA01000271A (es) | 1998-07-13 | 2002-10-17 | Expression Genetics Inc | Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable. |
PT1113785E (pt) | 1998-07-24 | 2005-08-31 | Seo Hong Yoo | Solucoes aquosas limpidas de acidos biliares |
KR100274842B1 (ko) | 1998-10-01 | 2001-03-02 | 김효근 | 미립구를 이용한 레티노익산의 서방형 약물방출 시스템 |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2790405B1 (fr) | 1999-03-02 | 2001-04-20 | Oreal | Nanocapsules a base de polymeres dendritiques |
US6245059B1 (en) * | 1999-04-07 | 2001-06-12 | Visx, Incorporated | Offset ablation profiles for treatment of irregular astigmation |
US6328988B1 (en) | 1999-04-23 | 2001-12-11 | Rutgers, The State University Of New Jersey | Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6050687A (en) * | 1999-06-11 | 2000-04-18 | 20/10 Perfect Vision Optische Geraete Gmbh | Method and apparatus for measurement of the refractive properties of the human eye |
US7098030B2 (en) | 1999-12-31 | 2006-08-29 | Mirus Bio Corporation | Polyampholytes for delivering polyions to a cell |
US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
US6234631B1 (en) * | 2000-03-09 | 2001-05-22 | Lasersight Technologies, Inc. | Combination advanced corneal topography/wave front aberration measurement |
DE10012151A1 (de) | 2000-03-13 | 2001-09-27 | Gsf Forschungszentrum Umwelt | Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD |
KR20010100194A (ko) | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
US6673062B2 (en) * | 2000-03-14 | 2004-01-06 | Visx, Inc. | Generating scanning spot locations for laser eye surgery |
WO2001072283A1 (en) | 2000-03-29 | 2001-10-04 | Aradigm Corporation | Cationic liposomes |
US6702806B2 (en) * | 2000-04-19 | 2004-03-09 | Alcon, Inc. | Eye registration and astigmatism alignment control systems and method |
US6338559B1 (en) * | 2000-04-28 | 2002-01-15 | University Of Rochester | Apparatus and method for improving vision and retinal imaging |
JP3785094B2 (ja) | 2000-05-02 | 2006-06-14 | エフ.ホフマン−ラ ロシュ アーゲー | 新規ガンマ選択的レチノイド |
US6896890B2 (en) | 2000-05-05 | 2005-05-24 | R.P. Scherer Technologies, Inc. | Oil-in-water emulsion formulation containing free and entrapped hydroquinone and retinol |
US6460997B1 (en) * | 2000-05-08 | 2002-10-08 | Alcon Universal Ltd. | Apparatus and method for objective measurements of optical systems using wavefront analysis |
US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
EP1341923A2 (en) * | 2000-08-29 | 2003-09-10 | Genentech, Inc. | Methods for enhancing the efficacy of cancer therapy |
US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6696483B2 (en) * | 2000-10-03 | 2004-02-24 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
WO2002032413A2 (en) * | 2000-10-17 | 2002-04-25 | Board Of Regents, The University Of Texas System | A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US7265186B2 (en) | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
CA2438235A1 (en) | 2001-02-16 | 2002-08-29 | Incyte Genomics, Inc. | Neurotransmission-associated proteins |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
EP1392366A4 (en) | 2001-04-13 | 2005-01-19 | Population Council Inc | INTRODUCTION EFFECTED THROUGH A NUCLEAR RECEPTOR OF A PNA PROTEIN IN CELL NUCLES |
US6472954B1 (en) * | 2001-04-23 | 2002-10-29 | Agilent Technologies, Inc. | Controlled effective coupling coefficients for film bulk acoustic resonators |
US6582079B2 (en) * | 2001-06-05 | 2003-06-24 | Metrologic Instruments, Inc. | Modular adaptive optical subsystem for integration with a fundus camera body and CCD camera unit and improved fundus camera employing same |
JP4547696B2 (ja) | 2001-06-07 | 2010-09-22 | 第一三共株式会社 | 肝硬変予防・治療剤 |
JP2002371006A (ja) | 2001-06-11 | 2002-12-26 | Mochida Pharmaceut Co Ltd | 肺線維症予防および/または進行防止剤 |
JP2005509593A (ja) | 2001-07-12 | 2005-04-14 | ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー | 薬物送達用の両親媒性星様高分子 |
US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
PT1443912E (pt) | 2001-10-12 | 2007-11-28 | Elan Pharma Int Ltd | Composições tendo uma combinação de características de libertação imediata e de libertação controlada |
US7297515B1 (en) | 2001-10-26 | 2007-11-20 | Myriad Genetics, Inc. | Zinc finger proteins |
DE60219677T2 (de) | 2001-10-30 | 2008-05-15 | Nektar Therapeutics Al, Corp., Huntsville | Wasserlösliche polymerkonjugate von retinoesäure |
JP3803318B2 (ja) | 2001-11-21 | 2006-08-02 | 株式会社RNAi | 遺伝子発現阻害方法 |
KR20100087400A (ko) | 2001-11-21 | 2010-08-04 | 가오루 사이고 | 유전자 발현 억제 방법 |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US6637884B2 (en) * | 2001-12-14 | 2003-10-28 | Bausch & Lomb Incorporated | Aberrometer calibration |
US20030147958A1 (en) | 2002-01-29 | 2003-08-07 | Cheol-Hee Ahn | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents |
AU2003216240A1 (en) * | 2002-02-11 | 2003-09-04 | Visx, Inc. | Closed loop system and method for ablating lenses with aberrations |
US20040106125A1 (en) | 2002-02-15 | 2004-06-03 | Duggan Brendan M | Neurotransmission-associated proteins |
US7018655B2 (en) | 2002-03-18 | 2006-03-28 | Labopharm, Inc. | Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions |
US6740676B2 (en) | 2002-03-19 | 2004-05-25 | Allergan, Inc. | 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7910594B2 (en) * | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
DK1565489T3 (da) | 2002-06-19 | 2011-03-07 | Raven Biotechnologies Inc | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet |
EP1519727A1 (en) | 2002-06-28 | 2005-04-06 | The Administrators of the Tulane Educational Fund | 4-(4-methylpiperazin-1-ylmethyl)-n- 4-methyl-3-(4-pyridin-3- yl)pyrimidin-2-ylamino)phenyl -benzamide for treating pulmon ary fibrosis |
WO2004013307A2 (en) | 2002-08-05 | 2004-02-12 | Mirus Corporation | Compounds for targeting hepatocytes |
JP2004083436A (ja) | 2002-08-23 | 2004-03-18 | Minofuaagen Seiyaku:Kk | 星細胞活性化抑制剤、及び、臓器線維症の予防又は治療剤 |
US20050191302A1 (en) | 2002-08-29 | 2005-09-01 | University Of Southampton | Treatment for liver disease |
US6740336B2 (en) | 2002-10-04 | 2004-05-25 | Mirus Corporation | Process for generating multilayered particles |
AU2003295474B2 (en) | 2002-11-13 | 2009-07-30 | Macrogenics West, Inc. | Antigen PIPA and antibodies that bind thereto |
JP4490291B2 (ja) | 2002-12-30 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | 薬物送達媒体としてのマルチアーム(multi−arm)ポリペプチド−ポリ(エチレングリコール)ブロックコポリマー |
US20040138154A1 (en) | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
WO2005000272A1 (en) * | 2003-06-04 | 2005-01-06 | Isis Pharmaceuticals, Inc. | Long-circulating liposomal compositions |
ES2321841T3 (es) | 2003-08-26 | 2009-06-12 | Smithkline Beecham Corporation | Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones. |
NZ545968A (en) | 2003-09-18 | 2010-01-29 | Raven Biotechnologies Inc | KID3 and KID3 antibodies that bind thereto |
US7064127B2 (en) | 2003-12-19 | 2006-06-20 | Mount Sinai School Of Medicine Of New York University | Treatment of hepatic fibrosis with imatinib mesylate |
KR20060123384A (ko) | 2003-12-24 | 2006-12-01 | 가부시키가이샤 엘티티 바이오파마 | 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제 |
US7297786B2 (en) | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
US7358223B2 (en) | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US20080014253A1 (en) | 2004-11-03 | 2008-01-17 | Kent Jorgensen | Lipid-Based Drug Delivery Systems Containing Unnatural Phospholipase A2 Degradable Lipid Derivatives and the Therapeutic Uses Thereof |
US7964571B2 (en) | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
ES2443229T3 (es) * | 2004-12-22 | 2014-02-18 | Nitto Denko Corporation | Portador de fármacos y kit portador de fármacos para la inhibición de la fibrosis |
JP4533420B2 (ja) | 2004-12-22 | 2010-09-01 | 日東電工株式会社 | 線維化抑制のための薬物担体および薬物担体キット |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US8246983B2 (en) * | 2005-09-02 | 2012-08-21 | Northwestern University | Encapsulated arsenic drugs |
JP5342834B2 (ja) | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
US7700541B2 (en) | 2006-04-06 | 2010-04-20 | Nitto Denko Corporation | Biodegradable cationic polymers |
WO2007143659A2 (en) | 2006-06-05 | 2007-12-13 | Massachusetts Institute Of Technology | Crosslinked, degradable polymers and uses thereof |
TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
US20080312174A1 (en) | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
CN101970012A (zh) | 2007-09-14 | 2011-02-09 | 日东电工株式会社 | 药物载体 |
CN102159247A (zh) | 2008-07-30 | 2011-08-17 | 日东电工株式会社 | 药物载体 |
-
2008
- 2008-03-27 TW TW097111089A patent/TWI407971B/zh not_active IP Right Cessation
- 2008-03-28 AR ARP080101305A patent/AR065878A1/es not_active Application Discontinuation
- 2008-03-28 US US12/450,571 patent/US8686052B2/en active Active
- 2008-03-28 WO PCT/JP2008/056735 patent/WO2008120815A1/ja active Application Filing
- 2008-03-28 CA CA002682493A patent/CA2682493A1/en not_active Abandoned
- 2008-03-28 ES ES08739842T patent/ES2793673T3/es active Active
- 2008-03-28 AU AU2008233550A patent/AU2008233550B2/en active Active
- 2008-03-28 JP JP2009507561A patent/JP5302187B2/ja active Active
- 2008-03-28 KR KR1020097020305A patent/KR101585947B1/ko active IP Right Grant
- 2008-03-28 EP EP08739842.6A patent/EP2135600B1/en active Active
- 2008-03-28 CN CN200880010916.8A patent/CN101674810B/zh active Active
-
2013
- 2013-06-19 JP JP2013128089A patent/JP2013224311A/ja not_active Withdrawn
-
2014
- 2014-01-08 US US14/150,478 patent/US20140127187A1/en not_active Abandoned
-
2015
- 2015-02-25 JP JP2015035066A patent/JP2015134789A/ja active Pending
-
2016
- 2016-11-02 JP JP2016215119A patent/JP2017048225A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2135600B1 (en) | 2020-04-29 |
JP2015134789A (ja) | 2015-07-27 |
JP5302187B2 (ja) | 2013-10-02 |
EP2135600A1 (en) | 2009-12-23 |
US20100144659A1 (en) | 2010-06-10 |
KR20090130010A (ko) | 2009-12-17 |
EP2135600A4 (en) | 2013-10-16 |
ES2793673T3 (es) | 2020-11-16 |
TWI407971B (zh) | 2013-09-11 |
JPWO2008120815A1 (ja) | 2010-07-15 |
CN101674810B (zh) | 2014-07-16 |
AU2008233550A1 (en) | 2008-10-09 |
US20140127187A1 (en) | 2014-05-08 |
KR101585947B1 (ko) | 2016-01-15 |
US8686052B2 (en) | 2014-04-01 |
WO2008120815A1 (ja) | 2008-10-09 |
TW200846022A (en) | 2008-12-01 |
JP2017048225A (ja) | 2017-03-09 |
CN101674810A (zh) | 2010-03-17 |
CA2682493A1 (en) | 2008-10-09 |
AU2008233550B2 (en) | 2013-02-21 |
JP2013224311A (ja) | 2013-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065878A1 (es) | Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer | |
Soria-Valles et al. | The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21 | |
Berindan-Neagoe et al. | Molecular pathways: microRNAs, cancer cells, and microenvironment | |
Zhang et al. | DNA‐hybrid‐gated multifunctional mesoporous silica nanocarriers for dual‐targeted and microRNA‐responsive controlled drug delivery | |
PE20190843A1 (es) | Arn de direccion a adn generico | |
WO2016106406A3 (en) | Rna agents for gst-pi gene modulation | |
HRP20231022T1 (hr) | Hibridni polinukleotidi crispr dna/rna i načini uporabe | |
AR110962A1 (es) | Composiciones y métodos de tratamiento de hemoglobinopatías | |
WO2015188197A3 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
Yu et al. | miRNAs regulate stem cell self-renewal and differentiation | |
WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
BR112015022507A2 (pt) | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados | |
EP3434773A3 (en) | Modulation of hsp47 expression | |
US20180344863A1 (en) | TDNs-AS1411-Nucleic Acid Drug Nanocomposite Based Drug Delivery System and Preparation Method Thereof | |
WO2016205410A3 (en) | Defined multi-conjugate oligonucleotides | |
BRPI0517131A2 (pt) | mÉtodos para simplificar Ácidos nuclÉicos microbiais por modificaÇço quÍmica de citosinas | |
EA201891629A1 (ru) | Способы и композиции для повышения эффективности нацеленной модификации генов с применением опосредуемой олигонуклеотидами репарации генов | |
WO2004009769A3 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS | |
EP2032714A4 (en) | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF NUCLEIC ACID | |
WO2005001110A3 (en) | Transcriptional regulation of gene expression by small double-stranded modulatory rna | |
WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
BR112018074304A2 (pt) | composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos | |
EP4218770A3 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
BR112021007403A2 (pt) | Composições e métodos para entrega de transgenes | |
Tu et al. | MicroRNAs mediated targeting on the Yin-yang dynamics of DNA methylation in disease and development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |